Insilico Medicine, Inc. — Form D/A
Insilico Medicine, Inc. of ROCKVILLE, MD, a company, filed a Form D amendment with the SEC on 2017-07-18. The offering totals $2.8M, of which $2.8M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2017-07-18
- Form: D/A
- Accession: 0001698493-17-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $2.8M
- Amount sold: $2.8M
- Minimum investment: $25K
- Investors: 17
- Date of first sale: 2016-12-10
- Security types: equity
- Revenue range: $1 - $1,000,000
- SEC file number: 021-281111
Issuer
- Name: Insilico Medicine, Inc.
- CIK: 0001698493
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2014
- Address: 9601 MEDICAL CENTER DR, SUITE 127, ROCKVILLE, MD, 20850
- Phone: 410-710-9674
Officers, directors & promoters (6)
| Name | Role | Location |
|---|
| James Mellon | Director | New York, NY |
| Alex Zhavoronkov | Director | Rockville, MD |
| Alex Zhavoronkov | Executive Officer | Rockville, MD |
| Qingsong Zhu | Executive Officer | Rockville, MD |
| Aleksandrs Zavoronkovs | Director | London, X0 |
| Aleksandrs Zavoronkovs | Executive Officer | London, X0 |
Other filings by this issuer (3)
More